CLEANWATTS
11.8.2022 12:43:09 CEST | Business Wire | Press release
Cleanwatts, the leading climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world, presents Soma Demeny as VP of HR, assuming the responsibility of leading our most important assets: people .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005340/en/
Soma Demeny began his career in Deutsche Telekom, subsequently spending 17 years with General Electric (GE) where he led human resource teams in Finance, Digital and Corporate divisions. Soma’s international career is centered on helping service and manufacturing organizations scale, grow and adapt to change through the implementation of world-class human resource infrastructures and best practices. More recently, Soma directed much of his time and expertise to help smaller mid-market companies reorganize and adapt to change.
Soma carries degrees in Business Studies and Human Resources Management and is a graduate of GE’s prestigious Human Resources Leadership Program. Soma is Hungarian and has lived in the UK, Austria, and South America. Among Soma’s defining characteristics are curiosity, agility, creativity and fun. As a father of two and a company cultural ambassador, this remains a key philosophy for Soma.
When asked why he joined Cleanwatts, Soma replied pointedly: “Who wouldn’t want to be part of changing the world?”
Cleanwatts’ appointment of Soma Demeny is yet another important decision taken by the company in recent months. It reflects Cleanwatts’ commitment to building a healthy, vibrant and talented organization able to travel at market speed. Michael Pinto, Cleanwatts co-founder and CEO, describes Soma as “a world-class HR Leader, out-of-the-box thinker and a person that connects very easily with people through his critical thinking, emotional intelligence, and clear communication style.”
Soma will be responsible for designing and overseeing the company’s HR strategy, including recruitment and employee retention programs, evaluating and improving the company’s employee value proposition, training and development plans, as well as creating a safe workplace, healthy and inspirational culture as the organization continues to build a world in which clean energy is decentralized, digitalized, and democratized.
Ends
About Cleanwatts
We are a climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world. We achieve this by optimizing the consumption, generation, storage, trading, and balancing of clean energy, where it matters most: locally.
We deliver value by creating and managing Renewable Energy Communities, deploying our domain expertise, proprietary technology, financial capital, and management capabilities for the benefit of our clients.
At the heart of our offering stands Cleanwatts™ OS, our Operating System specifically designed to manage energy communities. Cleanwatts™ OS is a modular, interoperable, and localizable cloud-based platform that seamlessly connects the dots between behind-the-meter optimization for community members, front-of-the-meter grid resiliency, and transaction management for local energy markets.
We are now actively managing a growing list of over 100 energy communities built by our very own REC Factory: a highly skilled cross-functional team, committed to working closely with anchor clients, town halls, and other community members to develop the best solution for each local community that we serve. Building on the success of our first REC Factory in Portugal, we’re now replicating this level of engagement in other geographies around the world.
We are building a world in which clean energy is decentralized, digitalized, and democratized.
Follow Cleanwatts on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
